Dr. Reddys Laboratories (RDY)
(Delayed Data from NYSE)
$75.21 USD
+0.43 (0.58%)
Updated May 3, 2024 04:00 PM ET
After-Market: $75.24 +0.03 (0.04%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth A Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
RDY 75.21 +0.43(0.58%)
Will RDY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for RDY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RDY
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
RDY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Here's Why Doctor Reddy's (RDY) is a Strong Value Stock
Other News for RDY
Dr. Reddy’s Introduces Generic Doxycycline in U.S.
Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
Dr. Reddy’s Faces Tax Demand, Plans Appeal
RDY Crosses Above Average Analyst Target
Dr. Reddy’s Forges Nutraceuticals JV; Leadership Changes